Direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer-associated venous thrombosis: a cost-effectiveness analysis.
Wei KangKuan PengVincent Ka Chun YanDaoud Al-BadriyehShing-Fung LeeHei Hang Edmund YiuYue WeiSilvia T H LiXuxiao YeAya El HelaliKa On LamVictor Ho Fun LeeIan Chi Kei Ck WongEsther Wai Yin ChanPublished in: Journal of pharmaceutical policy and practice (2024)
DOACs were associated with greater QALY improvements and lower overall costs compared to LMWH. Accounting for uncertainty, DOACs were between cost-effective and dominant in 57.9% of cases. DOACs are a cost-effective alternative to LMWH in the management of CAT in Hong Kong.